Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q4 2014 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$133.00K$133.00Kderived−29.6% vs Q4 2013 Net Income-$2.68M-$2.68MderivedN/M vs Q4 2013 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$2,665,000N/M Operating Cash Flowderived-$947,000N/M Free Cash Flowderived-$947,000N/M Margins · derivedOperating margin-2003.8%−860.9 pt vs Q4 2013
Net margin-2011.3%−869.0 pt vs Q4 2013
ended Jul 31, 2014 · filed Oct 28, 2014 · 89 d after period end